The Medicines Patent Pool (MPP) has announced a new, royalty-free licence agreement with AbbVie for glecaprevir/pibrentasvir (G/P) – a World Health Organization (WHO)-recommended treatment for people living with chronic hepatitis C (HCV).

The Medicines Patent Pool (MPP) announced that it has signed a Memorandum of Understanding (MoU) with Otsuka to accelerate the development and manufacturing of, and access to, paediatric formulations containing delamanid for multidrug-resistant tuberculosis (MDR-TB). Delamanid 50mg tablet was recently added to the World Health Organization’s Essential ...

Today, The Medicines Patent Pool and Gilead Sciences, Inc reported signing of a licensing agreement on the expansion of access to Bictegravir.

As part of a novel, once-daily, single-tablet HIV treatment, bictegravir could offer new option for people living with HIV in low- and middle-income countries Geneva, 4 October 2017 — The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under ...